Expertise in
14
conditions

Dr. Mark A. Goldstein

Naples, FL
Expertise in
14
conditions
Specialties:Internal Medicine
Expertise in
14
conditions
OverviewInsuranceLocationsClinical Research

Overview

Mark Goldstein is an Internal Medicine provider in Naples, Florida. Dr. Goldstein is highly rated in 14 conditions, according to our data. His top areas of expertise are Magnesium Deficiency, Gitelman Syndrome, Idiopathic Edema, and High Cholesterol.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 29 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield

Locations

132 Moorings Park Dr, Naples, FL 34105
239-430-6391

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

Long-Term Nicotine Treatment of Mild Cognitive Impairment
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drug: Nicotine Transdermal Patch
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Enrollment Status: Completed
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: CT1812
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Enrollment Status: Completed
Publish Date: July 31, 2024
Intervention Type: Drug, Other
Study Drug: Bryostatin I
Study Phase: Phase 2
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug, Other
Study Drug: Donanemab
Study Phase: Phase 2
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
Enrollment Status: Withdrawn
Publish Date: March 01, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
Development of a Biomarker Database to Investigate Aß, P-tau, and NfL Blood-Based Biomarkers and Digital Biomarkers in Older Participants Screened for Preclinical Alzheimer's Disease (AD), Prodromal AD, or Mild AD
Development of a Biomarker Database to Investigate Aß, P-tau, and NfL Blood-Based Biomarkers and Digital Biomarkers in Older Participants Screened for Preclinical Alzheimer's Disease (AD), Prodromal AD, or Mild AD
Enrollment Status: Completed
Publish Date: February 09, 2023
Intervention Type: Other
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
Enrollment Status: Terminated
Publish Date: November 17, 2022
Intervention Type: Radiation, Behavioral, Diagnostic test, Drug
Study Drug: Dihydrochloride Salt
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Enrollment Status: Completed
Publish Date: October 01, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2019
Intervention Type: Drug
Study Drug: BPN14770
Study Phase: Phase 2
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Enrollment Status: Completed
Publish Date: October 24, 2018
Intervention Type: Drug
View 26 Less Clinical Trials

1 Total Publications

Cyberbullying and Adolescents.
Cyberbullying and Adolescents.
Journal: Current pediatrics reports
Published: February 08, 2021
Similar Doctors
Expertise in
41
conditions
Dr. Bryan C. Murphey
Internal Medicine
Expertise in
41
conditions
Dr. Bryan C. Murphey
Internal Medicine

Nchmd Inc

15420 Collier Blvd, 
Naples, FL 
 (8.0 mi)
239-624-0600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bryan Murphey is an Internal Medicine provider in Naples, Florida. Dr. Murphey is highly rated in 41 conditions, according to our data. His top areas of expertise are High Cholesterol, Anemia, Obesity in Children, and Hypothyroidism. Dr. Murphey is currently accepting new patients.

Expertise in
9
conditions
Dr. Alberto F. Vera
Internal Medicine
Expertise in
9
conditions
Dr. Alberto F. Vera
Internal Medicine

Alberto F Vera PA

1713 Sw Health Pkwy, 
Naples, FL 
 (4.6 mi)
239-692-8719
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alberto Vera is an Internal Medicine provider in Naples, Florida. Dr. Vera is highly rated in 9 conditions, according to our data. His top areas of expertise are Stasis Dermatitis and Ulcers, Varicose Veins, Peptic Ulcer, and Osteomyelitis. Dr. Vera is currently accepting new patients.

Expertise in
25
conditions
Dr. Lawrence L. Kohn
Internal Medicine
Expertise in
25
conditions
Dr. Lawrence L. Kohn
Internal Medicine

Nchmd Inc

15420 Collier Blvd, 
Naples, FL 
 (8.0 mi)
239-624-0600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lawrence Kohn is an Internal Medicine provider in Naples, Florida. Dr. Kohn is highly rated in 25 conditions, according to our data. His top areas of expertise are Hypothyroidism, Obesity in Children, Glucocorticoid-Remediable Aldosteronism, and Hypertension. Dr. Kohn is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile